T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizumab) | BMJ Case Reports

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Global health

Authors

About

Help
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Case Reports: Adverse drug reactions and complications

T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizumab)

Online download statistics by month:

Online download statistics by month: March 2022 to April 2024

	Abstract	Full	Pdf
Mar 2022	205	6	2
Apr 2022	689	10	9
May 2022	304	9	2
Jun 2022	184	5	2
Jul 2022	69	0	0
Aug 2022	102	2	0
Sep 2022	105	3	1
Oct 2022	81	10	4
Nov 2022	96	4	4
Dec 2022	59	2	1
Jan 2023	18	0	1
Feb 2023	47	3	0
Mar 2023	59	7	2
Apr 2023	15	3	0
May 2023	31	0	0
Jun 2023	16	1	1
Jul 2023	37	1	0
Aug 2023	43	2	1
Sep 2023	26	2	0
Oct 2023	20	2	1
Nov 2023	25	2	1
Dec 2023	19	0	4
Jan 2024	27	1	0
Feb 2024	58	4	1
Mar 2024	28	4	1
Apr 2024	17	0	0
Total	2380	83	38